- Home
- CNTB vs IKNA Comparison
CNTB vs IKNA Comparison
Compare CNTB & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- IKNA
- Stock Information
- Founded
- CNTB 2012
- IKNA 2016
- Country
- CNTB United States
- IKNA United States
- Employees
- CNTB N/A
- IKNA N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- IKNA Health Care
- Exchange
- CNTB Nasdaq
- IKNA Nasdaq
- Market Cap
- CNTB 54.4M
- IKNA 63.7M
- IPO Year
- CNTB 2021
- IKNA 2021
- Fundamental
- Price
- CNTB $2.00
- IKNA N/A
- Analyst Decision
- CNTB Strong Buy
- IKNA Buy
- Analyst Count
- CNTB 2
- IKNA 2
- Target Price
- CNTB $7.50
- IKNA $13.50
- AVG Volume (30 Days)
- CNTB 280.7K
- IKNA 434.6K
- Earning Date
- CNTB 09-04-2025
- IKNA 07-24-2025
- Dividend Yield
- CNTB N/A
- IKNA N/A
- EPS Growth
- CNTB N/A
- IKNA N/A
- EPS
- CNTB N/A
- IKNA N/A
- Revenue
- CNTB $26,033,000.00
- IKNA N/A
- Revenue This Year
- CNTB N/A
- IKNA N/A
- Revenue Next Year
- CNTB N/A
- IKNA N/A
- P/E Ratio
- CNTB N/A
- IKNA N/A
- Revenue Growth
- CNTB N/A
- IKNA N/A
- 52 Week Low
- CNTB $0.51
- IKNA $0.97
- 52 Week High
- CNTB $2.86
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- CNTB 59.15
- IKNA 15.31
- Support Level
- CNTB $1.70
- IKNA $14.40
- Resistance Level
- CNTB $2.45
- IKNA $17.76
- Average True Range (ATR)
- CNTB 0.36
- IKNA 0.77
- MACD
- CNTB -0.02
- IKNA -1.96
- Stochastic Oscillator
- CNTB 42.51
- IKNA 0.00
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.